Qualigen Therapeutics Engages Professor Stephen Neidle as Scientific Advisor in the Development of Lead Program QN-302

<p>Innovator Behind Pancreatic Cancer-Focused Program Becomes Scientific Advisor CARLSBAD, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announced that it has engaged Professor Stephen Neidle as a scientific advisor. Professor Neidle is …</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/qualigen-therapeutics-engages-professor-stephen-neidle-as-scientific-advisor-in-the-development-of-lead-program-qn-302/">Qualigen Therapeutics Engages Professor Stephen Neidle as Scientific Advisor in the Development of Lead Program QN-302</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>